■α-肾上腺素能受体拮抗剂是减少BPH患者动态成分的最有效的药物疗法。然而,长期施用受体拮抗剂可引起mRNA受体表达上调,导致对药物有效性的耐受性。PKC-α通过激活电压门控Ca2传导管参与前列腺平滑肌收缩的过程,受雄激素激素的影响,尤其是睾丸激素,并与Twist1同工型,Twist1是一种在雄激素受体上调中发挥作用的转录因子。
■本研究的目的是比较长期坦索罗辛单药治疗和坦索罗辛-杜他雄胺联合治疗对Wistar大鼠前列腺基质组织PKC-α酶表达的影响。
■将80只大鼠样本分为8组,采用不同的干预措施:阴性对照组,阳性对照组,坦索罗辛单药治疗1天,3天,和6天组,和坦索罗辛-度他雄胺联合治疗1天,3天,6天组。用3mg/kg丙酸睾酮诱导BPH3周,根据干预分组继续用药。取前列腺基质组织,用ELISA法测定PKC-α酶。
■坦索罗辛单药治疗和坦索罗辛-度他雄胺联合治疗对PKC-α表达的影响存在显着差异(p<0.05)。坦索罗辛-度他雄胺联合治疗的持续时间对PKC-α表达有很强的正相关关系,这意味着坦索罗辛-度他雄胺组合的持续时间越长,PKC-α表达越高。
■长期服用坦索罗辛-度他雄胺联合治疗比仅服用坦索罗辛导致PKC-α表达上调。
UNASSIGNED: The α-adrenergic receptor antagonist is the most effective medical therapy to reduce the dynamic component in patients with BPH. However, long-term administration of receptor antagonists can cause
upregulation of mRNA receptor expression, resulting in tolerance of drug effectiveness. PKC-α is involved in the process of prostate smooth muscle contraction through activation of the voltage-gated Ca2+ conducted canal, influenced by androgen hormones, especially testosterone, and has an isoform with Twist1, a transcription factor that plays a role in up-regulation of androgen receptors.
UNASSIGNED: The aim of the study was to compare the effect of long-term tamsulosin monotherapy and tamsulosin - dutasteride combination therapy in PKC-α enzyme expression in prostate stromal tissue of Rattus norvegicus rats of Wistar strain.
UNASSIGNED: Out of 80 samples of Rattus norvegicus rats were divided into 8 groups with different interventions: negative control group, positive control group, tamsulosin monotherapy administration for 1 day, 3 day, and 6 day groups, and tamsulosin - dutasteride combination therapy for 1 day, 3 day, and 6 day groups. BPH was induced with 3 mg/kg of testosterone proprionate for 3 weeks, continued with drugs administration according to intervention grouping. Prostate stromal tissue was taken and prepared for PKC-α enzyme measurement with ELISA method.
UNASSIGNED: There was a significant difference (p<0.05) in the effect of tamsulosin monotherapy and tamsulosin-dutasteride combination therapy on the PKC-α expression. There was a strong positive relationship between the duration of tamsulosin-dutasteride combination therapy on the PKC-α expression, which means the longer the duration of the combination of tamsulosin-dutasteride combination the higher the PKC-α expression.
UNASSIGNED: Administration of long-term tamsulosin - dutasteride combination therapy causes
upregulation PKC-α expression more than tamsulosin only.